Incyte: Can Opzelura Offset Jakafi’s $3.7B Patent Cliff by 2028? 

Incyte Corporation’s recent financial and corporate update for the fourth quarter and full year 2024 showcases a year of significant growth and strategic progress. The company achieved a 15% increase in total revenues, reaching $4.2 billion for the year, driven by a robust 8% growth in Jakafi sales and a 50% surge in Opzelura revenues. The financial health of Incyte remains strong, with $2.2 billion in cash reserves and no debt, allowing the company to complete a $2 billion share repurchase program.